Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 39.00 | |
5 mg | In stock | $ 80.00 | |
10 mg | In stock | $ 139.00 | |
25 mg | In stock | $ 216.00 | |
50 mg | In stock | $ 278.00 | |
100 mg | In stock | $ 422.00 | |
500 mg | In stock | $ 957.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 64.00 |
Description | EN6-mediated ATP6V1A modification decouples the v-ATPase from the Rags, leading to inhibition of mTORC1 signaling, increased lysosomal acidification and activation of autophagy. EN6 clears TDP-43 aggregates, a causative agent in frontotemporal dementia, in a lysosome-dependent manner. EN6 is a small-molecule in vivo activator of autophagy that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal the vacuolar H+ ATPase (v-ATPase). |
Molecular Weight | 368.34 |
Formula | C19H14F2N4O2 |
CAS No. | 1808714-73-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.63 mg/mL (12.57 mM), Sonification is recommended.
Ethanol: 1.10 mg/mL (2.99 mM), Sonification and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EN6 1808714-73-9 Autophagy Membrane transporter/Ion channel Proton pump inhibit Inhibitor Proton Pump EN-6 EN 6 inhibitor